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Abstract
Background: MicroRNAs (miRNAs) are small non-coding RNAs that recognize sites of complementarity of target
messenger RNAs, resulting in transcriptional regulation and translational repression of target genes. In Huntington’s
disease (HD), a neurodegenerative disease caused by a trinucleotide repeat expansion, miRNA dyregulation has
been reported, which may impact gene expression and modify the progression and severity of HD.
Methods: We performed next-generation miRNA sequence analysis in prefrontal cortex (Brodmann Area 9) from 26
HD, 2 HD gene positive, and 36 control brains. Neuropathological information was available for all HD brains, including
age at disease onset, CAG-repeat size, Vonsattel grade, and Hadzi-Vonsattel striatal and cortical scores, a continuous
measure of the extent of neurodegeneration. Linear models were performed to examine the relationship of
miRNA expression to these clinical features, and messenger RNA targets of associated miRNAs were tested for
gene ontology term enrichment.
Results: We identified 75 miRNAs differentially expressed in HD brain (FDR q-value <0.05). Among the HD brains,
nine miRNAs were significantly associated with Vonsattel grade of neuropathological involvement and three of
these, miR-10b-5p, miR-10b-3p, and miR-302a-3p, significantly related to the Hadzi-Vonsattel striatal score (a continuous
measure of striatal involvement) after adjustment for CAG length. Five miRNAs (miR-10b-5p, miR-196a-5p, miR-196b-5p,
miR-10b-3p, and miR-106a-5p) were identified as having a significant relationship to CAG length-adjusted age of onset
including miR-10b-5p, the mostly strongly over-expressed miRNA in HD cases. Although prefrontal cortex was the
source of tissue profiled in these studies, the relationship of miR-10b-5p expression to striatal involvement in the disease
was independent of cortical involvement. Correlation of miRNAs to the clinical features clustered by direction of effect
and the gene targets of the observed miRNAs showed association to processes relating to nervous system development
and transcriptional regulation.
Conclusions: These results demonstrate that miRNA expression in cortical BA9 provides insight into striatal involvement
and support a role for these miRNAs, particularly miR-10b-5p, in HD pathogenicity. The miRNAs identified in our studies of
postmortem brain tissue may be detectable in peripheral fluids and thus warrant consideration as accessible biomarkers
for disease stage, rate of progression, and other important clinical characteristics of HD.
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Background
Huntington’s disease (HD) is an inherited disorder
caused by a CAG trinucleotide repeat expansion in HTT
which leads to progressive motor and cognitive impair-
ment due to the gradual loss of neurons within striatal
and cortical brain regions [1]. Although monogenic, HD
displays remarkable variation in clinical expression, most
readily observed by the range in age at clinical onset as
determined by the manifestation of motor symptoms,
varying from age 4 years to age 80 [2]. While onset age
is unequivocally related to the size of the expanded
CAG repeat, with longer repeats leading to earlier onset,
only 50% to 70% of the variation can be attributed to re-
peat size [3,4]. The remaining variation is highly herit-
able (h2 = 0.56), suggesting a strong role for genes that
modify disease progression [3].
MicroRNAs (miRNAs) are small non-coding RNAs
that negatively regulate the expression of genes in a
sequence-specific manner, binding to the 3′-untranslated
region (3′UTR) to initiate cleavage or translational re-
pression of target transcripts [5,6]. miRNAs influence a
diverse range of cellular processes [7] and consequently,
their altered expression may lead to or influence disease-
related pathological phenotypes, or reveal unknown aspects
of the disease process. In the central nervous system (CNS),
miRNAs are abundant, as brain-specific miRNAs assist in
various neuronal processes such as synaptic development,
maturation and plasticity [8,9]. Altered miRNA expression
has been observed in diseases of the CNS, particularly in
age-dependent neurodegenerative diseases, which suggests
that the expression of miRNAs may contribute to neuro-
pathogenesis [10,11].
In HD, the dysregulation of miRNAs has been re-
ported in HD in vitro models, transgenic HD animals
and human HD brain [12-24]. We hypothesize that post-
transcriptional regulation by miRNAs plays a role in
modifying the progression and severity of HD. Recently,
we completed a study of miRNA expression obtained
through next-generation sequencing technology in hu-
man HD and control brain samples to investigate the
presence of altered miRNA expression in HD and its
role in transcriptional dysregulation [13]. The original
study provided sample power to detect large miRNA
changes, but the sample size was not sufficient to detect
more subtle changes in miRNA expression and did not
represent a wide enough range of HD pathology to in-
vestigate relationships to clinical features of HD. There-
fore, to follow-up on these findings, we have sequenced
small RNAs in an additional 16 HD brains, two of which
are gene positive asymptomatic Vonsattel grade 0 cases,
and 27 control samples, for a combined study of 28 HD
and 36 control samples. The increased sample size en-
ables the detection of significantly altered miRNAs with
lower levels of differential expression as well as more
comprehensive characterization of the relationship of
these miRNAs to relevant clinical features of the disease,
including the age at motor onset of the disease, disease
duration (the time between onset and death), age at
death and extent of pathological involvement in the stri-
atum and cerebral cortex. A deeper understanding of the
global miRNA expression in HD may elucidate patho-
genic mechanisms of disease progression in HD and
suggest new therapeutic targets.
Results
Differential expression analysis highlights disrupted
miRNA expression in HD brain
To evaluate the relationship of miRNA expression to sa-
lient clinical and pathological features of HD, we profiled
miRNA expression using small RNA-sequencing of pre-
frontal cortex (Brodmann Area 9) of 26 symptomatic
HD and 36 control samples (see Table 1, Additional file
1: Table S1 and Additional file 2: Table S2). Although
the striatum is the most affected brain region in HD, dif-
ferences in miRNA expression between HD and un-
affected controls, independent of cellular composition,
would be difficult to assess due to the extent of neuron
loss and the increase of reactive astrocytosis in HD striatal
tissue [25]. Therefore, prefrontal cortex, which exhibits
hallmark characteristics of HD pathology [26], relates to
striatal involvement (Pearson r = 0.44, p < 2e-16) [27], but
experiences less extreme changes than the striatum
[28,29], was used for sequencing. In addition, previous
studies have found no difference in cell counts between
HD and controls from similar BA9 brain samples [13,30].
The HD samples consisted of Grade 2 (n = 4), Grade 3
(n = 15), and Grade 4 (n = 7) brains as determined by
Vonsattel grade, an assessment of striatal involvement
classified as 0 through 4 in order of the severity of
neuropathological involvement [25]. Sequenced samples
were also among the 523 HD brains characterized by the
recently established measure of pathological involvement
Table 1 Summary of the brain samples used for
miRNA-sequence analysis
Variable HD, grades
2 - 4
Asymptomatic
grade 0
Control
N 26 2 36
Age at death 59.5 ± 10.7 67.5 ± 26.1 68.6 ± 14.3
RNA integrity number 7.3 ± 0.9 7.7 ± 0.6 7.7 ± 0.7
Post mortem interval 15.7 ± 7.7 28.0 ± 7.9 14.4 ± 8.8
CAG repeat size 44.6 ± 2.9 42.0 ± 0
Age of onset 44.5 ± 11.8
Disease duration 15.0 ± 6.1
Striatal score 2.70 ± 0.65
Cortical score 1.25 ± 0.50
Hoss et al. BMC Medical Genomics  (2015) 8:10 Page 2 of 14
termed the Hadzi-Vonsattel score (H-V score), which
independently characterizes both striatal and cortical
pathological involvement in each brain [28]. While
Vonsattel grading and H-V striatal score are closely
related, (Pearson r = 0.90, measured using 346 HD
brains), H-V scores are a continuous metric and there-
fore more amenable to adjustment of covariates such
as CAG repeat size in modeling of neuropathological
involvement and independently assesses striatal and
cortical involvement. H-V scores ranged from 0–4,
where 0 indicates no detectable neuropathological in-
volvement and 4 indicates severe neuropathological
involvement. Samples from symptomatic individuals
had striatal scores ranging 1.43–3.82 and cortical
scores ranging from 0.40–2.36 (see Table 1, Additional
file 2: Table S2). Additionally, two Grade 0 brains
(both with CAG repeat expansions of 42 repeats) were
small-RNA sequenced and analyzed separately from
the 26 HD brains used in differential expression ana-
lysis. Grade 0 brains were neuropathologically normal
and asymptomatic at the time of death (see Table 1).
After processing sequencing data to remove sequencing
artifacts, normalize using variance stabilization transform-
ation, and adjust for batch effects (see Methods), 938 miR-
NAs were reliably quantified and 75 of these were
significantly differentially expressed in HD versus control
brains after adjusting for multiple comparisons (FDR q-
value < 0.05, see Table 2; see Additional file 3: Table S3 for
sequencing read statistics). In HD, 46 miRNAs were iden-
tified as significantly up-regulated and 29 as down-
regulated in their expression. Hox-related miRNAs had
the most extreme, positive fold changes, where miR-10b-
5p was 3.9 log2 fold increased, miR-196a-5p was 2.4 log2
fold increased, miR-615-3p was 1.6 log2 fold increased,
miR-10b-3p was 1.5 log2 fold increased, and miR-196b-5p
was 1.3 log2 fold increased (see Figure 1, see Table 2).
Both the 5′ and 3′ mature miRNAs were differentially
expressed for eight miRNA precursors (miR-10b, miR-
129, miR-1298, miR-142, miR-144, miR-148a, miR-302a,
and miR-486). In HD and controls, most 5′-3′ miRNA
pairs were positively correlated in their expression, with
the exception of miR-1298 in HD and miR-10b and miR-
302a in controls (Additional file 4: Table S4).
To confirm our previously published findings, we re-
analyzed the twelve HD and nine controls samples from
our original study using our updated sequence analysis
pipeline (see Methods) and then used the newly se-
quenced samples, consisting of 14 HD and 27 control
brains, as a replication set. Fourteen miRNAs were sig-
nificantly differentially expressed (FDR q-value < 0.05) in
the original set using the updated analysis pipeline, com-
pared to five differentially expressed miRNA in the ori-
ginal study. Fourteen differentially expressed miRNAs
were significantly differentially expressed in the replication
set and thirteen of these fourteen were significant in the
combined sequence analysis. As previously reported, Hox-
related miRNA, including miR-10b-5p, were among the
most strongly differentially expressed across all three stud-
ies (see Table 2).
Firefly Bioworks microRNA assay, a multiplexed,
particle-based technology using flow cytometry to measure
miRNA levels, was used to quantify and orthogonally valid-
ate miRNA differential expression from sequencing (see
Methods). A subset of 21 controls and 15 HD samples from
the sequencing study were selected for the assay. Sixteen
miRNAs with moderately high expression levels were se-
lected for testing and an additional six miRNAs were used
as input normalizers (Additional file 5: Table S5). miR-10b-
5p was confirmed as significant after correcting for multiple
corrections (p-value = 3.0e-10, q-value = 6.6e-9). Seven out
of sixteen miRNAs assayed approached but did not reach
significance after adjustment in this subset (unadjusted p-
value < 0.05, miR-10b-5p, miR-194-5p, miR-223-3p, miR-
132-3p, miR-144-5p, miR-148a-3p, miR-486-5p). Eight of
the remaining nine miRNAs that failed to achieve signifi-
cance had the same direction of effect (Additional file 5
Table S5). These results were consistent with the reduced
power available from this subset.
Nine miRNAs relate to Vonsattel grade
To explore the relationship of miRNA expression to
principal clinical aspects of the disease, we next modeled
the expression of the 75 differentially expressed miRNAs
to the Vonsattel grade of neuropathological involvement.
Analysis of variance (ANOVA) was performed to com-
pare the expression of the 75 differentially expressed
miRNAs across Vonsattel grade in all 28 (Grade 0–4)
HD gene-positive and control brains. 65 miRNA were
found to be significant in the ANOVA (FDR-adjusted q-
value < 0.05), indicating differential expression may be
driven by the difference of controls to specific grades.
Next, ANOVA was performed exclusively in HD brains
to find whether miRNA differences exist across Vonsattel
grades. Nine miRNAs were significant in both ANOVA
tests after adjusting for multiple comparisons, indicating a
significant difference in the expression of these miRNAs
across Vonsattel grades (both FDR q-values < 0.05;
Additional file 6: Table S6). Last, pairwise comparisons
of each grade with the control group were performed
using post-hoc Tukey’s HSD (honestly significant different)
tests to find specific groups that significantly differed from
one another. Figure 2 highlights the nine miRNAs that are
associated with grade in order of statistical significance
from the ANOVA inclusive of control brains in the test. In
Figure 2, significant differences across grade and control
groups as determined by Tukey HSD are denoted by letters
(a-d) in the grey banner above each boxplot, whereby
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Table 2 Differentially expressed miRNAs in Huntington’s disease prefrontal cortex
miRNA Average
expression
Original study, N=21 Replication study, N=41 Combined study, N=64
logFC p-value FDR q-value logFC p-value FDR q-value logFC p-value FDR q-value
miR-10b-5p 11.62 4.31 4.56E-11 4.28E-08 3.40 4.30E-12 1.35E-09 3.94 1.28E-20 1.20E-17
miR-196a-5p 2.41 2.18 1.66E-09 7.80E-07 2.13 3.42E-12 1.35E-09 2.35 2.97E-20 1.39E-17
miR-615-3p 1.95 1.28 1.69E-06 3.97E-04 1.73 2.56E-13 2.40E-10 1.59 2.33E-16 7.28E-14
miR-10b-3p 2.02 1.37 4.64E-07 1.45E-04 1.15 2.93E-06 6.88E-04 1.45 2.13E-12 4.98E-10
miR-1298-3p 7.05 −0.56 1.72E-03 9.47E-02 −0.80 1.09E-05 2.04E-03 −0.78 5.52E-09 1.03E-06
miR-196b-5p 2.56 1.05 7.62E-05 1.02E-02 1.06 9.34E-04 5.84E-02 1.31 2.33E-08 3.64E-06
miR-302a-3p 2.28 0.64 6.22E-03 1.94E-01 0.84 3.57E-04 2.79E-02 0.81 3.72E-06 4.98E-04
miR-1247-5p 6.18 0.90 2.05E-05 3.84E-03 0.46 7.81E-03 1.63E-01 0.62 8.47E-06 9.55E-04
miR-144-3p 10.26 0.80 4.48E-02 3.73E-01 1.09 2.63E-04 2.47E-02 1.08 9.16E-06 9.55E-04
miR-223-3p 8.46 0.49 3.95E-02 3.54E-01 0.94 6.20E-05 7.33E-03 0.75 1.94E-05 1.82E-03
miR-3200-3p 9.75 −0.25 8.48E-02 4.65E-01 −0.29 4.20E-03 1.31E-01 −0.32 4.85E-05 4.14E-03
miR-302a-5p 2.99 0.52 2.86E-03 1.28E-01 0.62 1.97E-02 2.66E-01 0.70 5.70E-05 4.46E-03
miR-1264 5.00 −0.24 1.09E-01 5.15E-01 −0.69 3.87E-04 2.79E-02 −0.53 9.49E-05 6.36E-03
miR-6734-5p 2.79 −0.34 1.89E-01 6.19E-01 −1.16 1.63E-05 2.55E-03 −0.79 8.86E-05 6.36E-03
miR-144-5p 9.30 0.51 1.43E-01 5.71E-01 1.13 3.31E-04 2.79E-02 0.94 1.04E-04 6.53E-03
miR-138-2-3p 6.08 −0.44 3.59E-03 1.41E-01 −0.29 3.24E-02 3.01E-01 −0.38 1.43E-04 8.38E-03
miR-431-5p 5.65 −0.49 2.33E-02 3.09E-01 −0.51 7.64E-03 1.63E-01 −0.57 1.60E-04 8.84E-03
miR-132-3p 12.93 −0.48 1.57E-02 2.60E-01 −0.43 2.72E-02 2.89E-01 −0.54 1.99E-04 9.31E-03
miR-200c-3p 3.84 0.46 3.97E-02 3.54E-01 0.26 1.12E-01 4.84E-01 0.48 1.97E-04 9.31E-03
miR-23b-5p 3.18 −0.30 8.92E-02 4.66E-01 −0.62 2.02E-03 9.46E-02 −0.55 1.81E-04 9.31E-03
miR-448 4.02 −0.14 5.66E-01 8.91E-01 −0.80 9.98E-05 1.04E-02 −0.64 2.23E-04 9.96E-03
miR-486-3p 4.84 0.54 7.85E-02 4.57E-01 0.79 4.16E-03 1.31E-01 0.78 2.76E-04 1.04E-02
miR-490-5p 5.56 −0.45 6.53E-02 4.34E-01 −0.56 1.15E-02 2.12E-01 −0.62 2.62E-04 1.04E-02
miR-5695 3.30 0.38 3.04E-02 3.28E-01 0.48 4.02E-03 1.31E-01 0.47 2.73E-04 1.04E-02
miR-885-5p 10.46 −0.31 5.23E-02 4.07E-01 −0.27 3.12E-02 3.01E-01 −0.35 2.77E-04 1.04E-02
miR-1224-5p 8.08 −0.39 3.89E-02 3.54E-01 −0.53 4.83E-03 1.39E-01 −0.49 3.83E-04 1.20E-02
miR-1298-5p 6.43 −0.80 9.80E-03 2.17E-01 −0.65 3.24E-02 3.01E-01 −0.81 3.84E-04 1.20E-02
miR-142-3p 8.13 0.20 3.09E-01 7.41E-01 0.62 1.70E-03 8.39E-02 0.52 3.84E-04 1.20E-02
miR-346 8.21 −0.31 6.05E-02 4.26E-01 −0.27 1.74E-02 2.66E-01 −0.32 3.71E-04 1.20E-02
miR-891a-5p 5.84 0.79 5.16E-05 8.07E-03 0.18 3.68E-01 7.04E-01 0.50 3.69E-04 1.20E-02
miR-16-2-3p 7.23 0.30 3.45E-01 7.53E-01 0.83 6.97E-04 4.67E-02 0.71 3.98E-04 1.21E-02
miR-363-3p 11.07 0.39 1.08E-02 2.20E-01 0.30 2.71E-02 2.89E-01 0.34 4.14E-04 1.21E-02
miR-148a-3p 13.01 0.69 1.70E-02 2.60E-01 0.47 7.34E-02 4.18E-01 0.69 4.57E-04 1.29E-02
miR-199a-5p 7.66 0.69 3.46E-02 3.35E-01 0.66 4.30E-02 3.45E-01 0.82 4.66E-04 1.29E-02
miR-4449 3.25 −0.96 1.83E-03 9.51E-02 −0.86 5.21E-02 3.68E-01 −1.09 5.28E-04 1.42E-02
miR-106a-5p 6.28 0.52 9.97E-03 2.17E-01 0.40 3.15E-02 3.01E-01 0.44 5.64E-04 1.43E-02
miR-142-5p 11.47 0.20 4.43E-01 8.36E-01 0.71 1.66E-03 8.39E-02 0.60 5.77E-04 1.43E-02
miR-549a 3.25 0.57 9.95E-02 4.89E-01 0.86 1.84E-02 2.66E-01 0.95 5.67E-04 1.43E-02
miR-214-5p 3.99 0.81 8.21E-03 2.12E-01 0.42 2.23E-01 5.96E-01 0.84 6.62E-04 1.59E-02
miR-141-3p 5.43 0.48 1.12E-01 5.20E-01 0.34 2.00E-02 2.66E-01 0.47 8.05E-04 1.89E-02
miR-5680 5.39 −0.20 1.92E-01 6.23E-01 −0.41 5.42E-03 1.40E-01 −0.35 9.93E-04 2.27E-02
miR-3065-5p 6.04 0.37 1.10E-01 5.15E-01 0.40 6.86E-03 1.57E-01 0.42 1.04E-03 2.33E-02
miR-224-5p 4.95 0.71 5.90E-02 4.20E-01 0.82 1.98E-02 2.66E-01 0.88 1.19E-03 2.60E-02
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groups with different letters are significantly different from
one another while those which share letters are not.
Several patterns in the relationship of grade to miRNA
expression were observed. First, the expression of miR-
10b-5p was significant in nearly all comparisons; pair-
wise contrasts between all grades as well as with the
control group were different except for grade 0, although
grade 0 was different than grades 2, 3 and 4 (see
Figure 2A). Second, the expression of miRNAs in
grade 0 brains was rarely different than controls,
with the exception of miR-200c-3p, where its expres-
sion in grade 0 brains was significantly lower than
both controls and grades 2–4 brains (see Figure 2G).
Third, the expression of miRNAs in grade 3 and 4
Table 2 Differentially expressed miRNAs in Huntington’s disease prefrontal cortex (Continued)
miR-4787-3p 5.94 −0.25 1.84E-01 6.15E-01 −0.30 1.29E-02 2.23E-01 −0.33 1.23E-03 2.62E-02
miR-452-5p 4.76 0.32 2.06E-01 6.41E-01 0.68 2.02E-02 2.66E-01 0.67 1.29E-03 2.69E-02
miR-129-1-3p 9.79 −0.42 3.13E-02 3.33E-01 −0.28 5.47E-02 3.79E-01 −0.38 1.36E-03 2.76E-02
miR-4443 5.69 0.92 1.10E-02 2.20E-01 0.41 1.54E-01 5.39E-01 0.75 1.39E-03 2.77E-02
miR-101-5p 9.55 0.30 2.49E-02 3.11E-01 0.20 1.08E-01 4.74E-01 0.28 1.47E-03 2.88E-02
miR-483-5p 4.39 1.03 5.31E-02 4.07E-01 0.78 8.24E-02 4.31E-01 1.16 1.52E-03 2.91E-02
miR-2114-5p 3.41 0.39 3.34E-02 3.33E-01 0.29 1.85E-01 5.72E-01 0.48 1.65E-03 3.09E-02
miR-1185-1-3p 5.32 −0.24 2.34E-01 6.71E-01 −0.43 8.49E-03 1.67E-01 −0.41 1.70E-03 3.12E-02
miR-670-3p 6.70 −0.46 5.50E-02 4.13E-01 −0.39 7.24E-02 4.18E-01 −0.52 1.77E-03 3.19E-02
miR-129-5p 12.39 −0.13 3.31E-01 7.47E-01 −0.50 3.31E-03 1.20E-01 −0.35 1.95E-03 3.22E-02
miR-135b-5p 4.45 −0.49 1.70E-02 2.60E-01 −0.44 5.58E-02 3.82E-01 −0.52 1.97E-03 3.22E-02
miR-194-5p 8.77 0.23 8.25E-02 4.64E-01 0.32 3.68E-02 3.29E-01 0.33 1.99E-03 3.22E-02
miR-208b-3p 6.41 0.46 1.10E-02 2.20E-01 0.28 7.05E-02 4.18E-01 0.36 1.89E-03 3.22E-02
miR-4488 2.97 −1.38 3.79E-04 3.24E-02 −0.91 1.35E-01 5.16E-01 −1.32 1.96E-03 3.22E-02
miR-888-5p 2.83 0.56 3.39E-02 3.35E-01 0.39 7.20E-02 4.18E-01 0.56 1.91E-03 3.22E-02
miR-126-5p 15.88 0.41 2.59E-02 3.16E-01 0.23 6.10E-02 4.03E-01 0.29 2.46E-03 3.88E-02
miR-34c-5p 9.25 −1.09 6.77E-04 4.75E-02 −0.40 1.41E-01 5.26E-01 −0.64 2.48E-03 3.88E-02
miR-218-1-3p 6.08 0.30 5.80E-02 4.20E-01 0.39 2.29E-02 2.76E-01 0.35 2.53E-03 3.89E-02
miR-150-5p 10.20 0.42 2.03E-02 2.84E-01 0.33 6.04E-02 4.02E-01 0.39 2.74E-03 4.11E-02
miR-486-5p 14.08 0.70 7.24E-02 4.52E-01 0.66 4.08E-02 3.39E-01 0.75 2.76E-03 4.11E-02
miR-433-3p 10.55 −0.01 9.48E-01 9.91E-01 −0.36 1.23E-03 7.24E-02 −0.24 2.85E-03 4.18E-02
miR-219b-3p 3.11 −0.46 1.89E-02 2.78E-01 −0.24 3.09E-01 6.46E-01 −0.47 3.05E-03 4.40E-02
miR-548n 2.82 0.09 6.44E-01 9.27E-01 0.64 6.41E-03 1.50E-01 0.52 3.14E-03 4.46E-02
miR-663b 2.20 −0.73 1.49E-02 2.59E-01 −0.59 9.97E-02 4.58E-01 −0.81 3.21E-03 4.50E-02
miR-148a-5p 6.67 0.46 4.67E-02 3.81E-01 0.44 7.58E-02 4.18E-01 0.52 3.31E-03 4.57E-02
miR-29a-3p 15.37 0.20 1.33E-01 5.56E-01 0.22 4.17E-02 3.40E-01 0.23 3.46E-03 4.70E-02
miR-320b 5.63 1.13 1.69E-02 2.60E-01 0.56 1.93E-01 5.78E-01 0.97 3.54E-03 4.74E-02
miR-181a-3p 12.15 −0.43 2.97E-02 3.26E-01 −0.29 9.44E-02 4.51E-01 −0.38 3.60E-03 4.75E-02
miR-153-5p 7.32 0.55 7.08E-03 2.05E-01 0.22 1.80E-01 5.72E-01 0.37 3.78E-03 4.79E-02
miR-28-5p 10.13 0.24 1.37E-01 5.65E-01 0.22 6.84E-02 4.14E-01 0.27 3.75E-03 4.79E-02
miR-7-2-3p 6.06 0.25 8.90E-02 4.66E-01 0.26 4.67E-02 3.59E-01 0.27 3.78E-03 4.79E-02
miR-877-5p 7.14 −0.28 1.28E-01 5.50E-01 −0.29 2.07E-02 2.66E-01 −0.28 3.88E-03 4.85E-02
miR-3687 4.14 −1.37 3.47E-04 3.24E-02 −0.77 1.96E-01 5.78E-01 −1.20 4.25E-03 5.17E-02
miR-4516 3.82 −1.29 3.03E-04 3.16E-02 −0.77 1.72E-01 5.61E-01 −1.13 4.42E-03 5.24E-02
miR-3139 3.01 −0.82 4.64E-04 3.63E-02 0.00 9.86E-01 9.94E-01 −0.48 9.64E-03 8.37E-02
miR-663a 2.56 −1.02 1.61E-04 1.89E-02 −0.46 3.60E-01 6.98E-01 −0.86 1.40E-02 1.04E-01
miR-34b-3p 5.11 −0.92 7.09E-04 4.75E-02 −0.24 3.87E-01 7.16E-01 −0.49 1.77E-02 1.20E-01
miR-1538 2.63 0.20 3.04E-01 7.41E-01 −0.70 6.26E-05 7.33E-03 −0.21 1.30E-01 3.68E-01
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brains appeared relatively similar to one another,
with the exception of miR-10b-5p, as mentioned
above, and miR-4488, where grade 3 brains were sig-
nificantly lower than all other groups (see Figure 2D).
Although not significant in the HD-only ANOVA, sig-
nificant pairwise differences between grade 3 and 4
were observed for miR-1298-5p (Bonferroni q-value =
3.6e-2) and miR-615-3p (Bonferroni q -value = 2.2e-2).
To assess the sensitivity and specificity of miR-10b-5p
for predicting HD, area under the curve (AUC) values
were calculated using receiver operating characteristic
curves (ROC). When comparing HD to controls to pre-
dict HD, the AUC was 99.47% (95% confidence level was
98.46%-100%). In a comparison of asymptomatic HD to
HD to predict HD status, the AUC was 98.08% (95%
confidence level was 92.75-100%) and comparing asymp-
tomatic HD to controls, the AUC was 84.72% (95% CI:
71.09%-98.36%).
miRNA expression relates to striatal involvement and age
of onset in HD
To further elucidate the meaning of the associations of
the miRNAs to HD, we examined the relationship be-
tween the 75 differentially expressed miRNAs and other
salient features of the disease (age at motor onset, dis-
ease duration, age at death, and H-V scores of striatal
and cortical involvement). To avoid confounding the
analysis of these clinical features by the known, strong
relationship between HTT CAG repeat size and disease
pathology and onset [4,28,31,32], CAG-adjusted resid-
uals were calculated for all continuous clinical traits
(see Additional file 7: Figure S1).
Using linear regression analysis and applying FDR-
adjustment for the 75 comparisons, three miRNAs (miR-
10b-5p, miR-10b-3p, miR-302a-3p) were observed to
have a significant relationship to CAG-adjusted striatal
score (FDR q-values = 2.28e-2). All three were significant
in the analysis of miRNA expression to Vonsattel grade
(see above). Additionally, five miRNAs were identified as
having significant association to CAG-adjusted age of
onset (miR-10b-5p, FDR q-value = 3.49e-3; miR-196a-5p,
FDR q-value = 1.32e-2; miR-196b-5p, FDR q-value =
1.71e-2; miR-10b-3p, FDR q-value = 1.71e-2; miR-106a-
5p, FDR q-value = 1.71e-2). Figure 3 highlights the rela-
tionship of miR-10b to CAG-adjusted striatal score and
onset, where both 3p and 5p mature sequences of miR-
10b were the only miRNA species to have significant, lin-
ear association to these two clinical features independent
of CAG effect. No FDR-significant relationships of miRNA
to disease duration or death age were observed.
No significant relationship of the expression of the 75
differentially expressed miRNA to CAG-adjusted cortical
score was observed, although nominal associations were
seen. In order to account for the potential impact of cor-
tical involvement on the relationship of miRNA expres-
sion to striatal involvement, we performed a multivariate
regression analysis modeling miRNA expression to stri-
atal H-V score while correcting for cortical H-V score.
After CAG-adjusted cortical score correction, CAG-
adjusted striatal score remained significant (miR-10b-5p
p-value = 0.04, miR-10b-3p p-value = 0.01, miR-302a-3p
p-value = 0.005).
Last, to characterize the patterns of association of
miRNAs to clinical features, Pearson coefficients of
the correlation of the expression of the differentially
expressed miRNAs to five CAG-adjusted features (on-
set age, disease duration, death age, striatal score and
cortical score) were hierarchically clustered. Grade 0
and controls samples were not included in these ana-
lyses. Correlation coefficients rather than beta coeffi-
cients were used in order to standardize the direction
of effect. Here, we observed differentially expressed
miRNAs with correlation p-values < 0.05 clustered
into distinguishable patterns of association to clinical
variables (see Figure 4). Differentially expressed miR-
NAs increased in HD compared to controls tended
to have negative correlations with onset and death,
and positive correlations with striatal and cortical
score. Conversely, differentially expressed miRNAs
with negative relative fold changes had positive cor-
relations with onset and death, and negative correla-
tions with striatal and cortical scores.
Figure 1 Characterization of miRNA in Huntington’s disease
brain. Volcano plot of 75 significantly differentially expressed miRNA
after FDR-adjustment for 938 comparisons. Points labeled red were
up-regulated in HD and points labeled as blue were down-regulated
in HD. Hox-related miRNA points are labeled and represent the top
differentially expressed miRNA in HD.
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Targets of HD-related miRNAs are associated with nervous
system development and transcriptional regulation
To attempt to understand the potential functional im-
pact of miRNA dysregulation in HD, gene ontology en-
richment was performed using predicted targets for
miRNAs that correlated with clinical features and were
suitably annotated in Targetscan (twelve miRNAs in
total). 5712 unique mRNA targets for miRNAs with
positive fold change in HD (miR-106a/302a-5p, miR-
196a/miR-196b, miR-302a-3p, miR-363, miR-10b, miR-
615-3p), and 6572 mRNA targets for negative fold
change in HD (miR-129-3p, miR-129-5p, miR-132-3p,
miR-4449, miR-4488, miR-490-5p) were found using
Targetscan [33], and stratified by fold change for gene
A B C
D E F
G H I
Figure 2 Nine miRNAs are associated with Vonsattel grade. In HD brains, expression of differentially expressed miRNA was compared across
Vonsattel grades 0–4. Boxplots represent nine FDR-significant miRNAs (A. miR-10b-5p, B. miR-196a-5p, C. miR-10b-3p, D. miR-196b-5p, E. miR-302a-3p,
F. miR-200c-3p, G. miR-4488, H. miR-4449, I. miR-663b) (FDR q < 0.05, adjusted for 75 contrasts) associated with Vonsattel grade by analysis of variance
(ANOVA). X-axes represent Vonsattel grade, classified 0–4 in order of the severity of striatal involvement and Y-axes show the VST expression values after
batch correction. Significant differences across grades and controls are denoted by letters in the grey banner above the boxplot, labeled a-d. Groups
with different letters are significantly different from one another while those with the same letter are not, after correcting for multiple comparisons. For
example, group “a” would be significantly different from group “b” and “c.” Conditions represented by multiple letters indicate no significant difference
among those groups. For example, group “ab” would not be significantly different than groups “a” and “b,” but would be different group “c.”
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ontology term (GO) enrichment analysis. Using Top-
GO’s weight algorithm with Fisher’s Exact Test for gene
ontology term enrichment and a weighted p-value cut-
off less than p < 0.05, 354 GO Biological Processes, 86
GO Molecular Functions and 62 GO Cellular Com-
ponent terms for mRNA targets of down-regulated
miRNA were significant. 260 GO Biological Pro-
cesses, 78 GO Molecular Functions, 48 GO Cellular
Component terms for mRNA targets of up-regulated
miRNA were significant.
To make these long lists of GO terms more intelli-
gible, terms were summarized using semantic similarity
measures to remove gene-set and GO term redundancy
(see Methods).
Targets of up- and down-regulated miRNAs had substan-
tial overlap in their overall function. Three of the top
twenty collapsed GO Biological Processes terms were
shared between the two sets of targets (see Figure 5A).
These terms were “nervous system development,” “Fc-
epsilon receptor signaling pathway,” and “proteasome
−mediated ubiquitin − dependent protein catabolic
process.” “Nervous system development” was the most
significant term in both sets (Up p = 8.5e-5, Down p =
9.9e-7). The top enriched term was “positive regula-
tion of transcription, DNA-templated”, (N = 1678, p =
2.7e-4) for the positive gene set and “synaptic trans-
mission”, (N = 3166, p = 3.4e-6) for the negative gene
set. Of the 78 up-regulated Molecular Function terms
and 86 down-regulated terms, fifteen terms were the
same (see Figure 5B). Top terms were included “se-
quence-specific DNA binding transcription factory ac-
tivity”, “sequence-specific DNA binding” and “calcium
ion binding”. Though shared between the two groups,
“transcription factor binding” was enriched higher in
down-regulated miRNAs than positive ones. For GO
Cellular Component, six terms were the same between
the two gene sets. These terms included “nucleus” and
“cytoplasm” as well as “cell junction” (see Figure 5C).
A B
C D
Figure 3 miR-10b is associated with age of onset and striatal involvement. In 26 Vonsattel grade 2, 3 and 4 HD brains, both mature miR-10b
sequences (−5p and −3p) have FDR-significant relationships to CAG-adjusted Hadzi-Vonsattel striatal score (A and B) and CAG-adjusted onset
age (C and D). Y-axes show the variance stabilizing transformation expression values after batch correction and shows that miR-10b-5p is
expressed at much higher levels than miR-10b-3p. Grade 0 cases are not included, as they have neither onset age nor H-V striatal score.
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Discussion
In a next-generation sequence analysis of small non-
coding RNAs in 26 HD and 36 control brains we de-
tected 938 miRNAs and 75 of these were differentially
expressed. All five miRNAs reported as differentially
expressed in our previous study (miR-10b-5p, miR-196a-
5p, miR-196b-5p, miR-615-3p and miR-1247-5p) were
significantly differentially expressed in this study [13].
These results were independently validated in the 41 (14
HD and 27 control brains) newly studied brains (see
Table 2), and support the presence and robust up-
regulation of Hox-related miRNAs in HD brain [13].
The increased number of differentially expressed miR-
NAs is likely due to an increase in sample size. Increas-
ing our sample size (from N = 21 to N = 62) enhanced
the statistical power to detect additional miRNAs with
smaller but significant changes in miRNA expression.
We believe these miRNA signals are not attributed to a
change in BA9 architecture, influenced by neuronal cell
death or reactive glial response, because cell numbers
between HD and controls from the same brain samples
were indistinguishable [13,30].
Dysregulation of several miRNAs from our study have
been observed in HD in other contexts. Concordant with
our findings, miR-132-3p down-regulation in human HD
parietal cortical tissue [15] and in brains of R6/2 and
YAC128 HD mouse models has been observed [15,18].
miR-132 is highly enriched in the brain [34,35] and its ex-
pression has been shown to affect neuron morphogenesis
and enhance neurite outgrowth by suppressing the
GTPase-activating protein p250GAP (p250GAP/RICS)
[36]. Another target of miR-132 is acetylcholinesterase
(ACHE), which encodes an enzyme responsible for the
breakdown of the neurotransmitter acetylcholine at the
neural synapse [37]. Acetylcholinesterase is critically in-
volved in cognition, and acetylcholinesterase inhibitors are
FDA-approved for the treatment of cognitive impairments
in Alzheimer’s disease [37]. Thus, decreased miR-132
levels may negatively impact brain health, through the
dysregulation of p250GAP (limiting its suppression) and
ACHE (indirectly decreasing acetylcholine levels).
Differentially expressed miRNAs may also target HTT
transcripts as a response to mutant HTT to reduce HTT
transcriptional levels and limit toxicity. miRNAs that target
the HTT 3′UTR and reduce HTT transcript levels in vitro,
miR-148a-5p, miR-150-5p and miR-214-5p, were signifi-
cantly up-regulated in their expression [21,38]. Although
miR-196a does not directly target HTT [33], increased miR-
196a expression was observed in a primate model of HD
and its over-expression in vitro and in animal transgenic
models suppressed mutant HTT expression [24]. The miR-
NAs with the largest effect in our study, miR-10b-5p, puta-
tively targets HTT by binding to two 3′UTR sites (both
7mer-1A seed, positions 2742–2748 and 3301–3307) and
may reduce expression of HTT although it is not clear
whether or not this would be neuroprotective [33].
However, miR-10b-5p also targets brain-derived neuro-
trophic factor (BDNF) [39], a growth factor required for the
survival and differentiation of striatal neurons [40]. BDNF
has been extensively studied in HD [41], as normal hun-
tingtin protein is reported to up-regulate BDNF levels,
while mutant huntingtin impairs BDNF protein abundance
which may consequently lead to death of striatal neurons
[42]. Because of the potential biological importance of
BDNF, and the possibility that miR-10b-5p may diminish
translation of BDNF, over-expression of miR-10b-5p might
be harmful to neuronal cells. However, in Hoss et al. [13],
we showed that ectopic expression of miR-10b-5p in PC12
Figure 4 CAG-adjusted clinical features of HD show patterns of association with miRNA expression. CAG-adjusted measures of onset age,
disease duration, death age, Hadzi-Vonsattel (H-V) striatal and cortical score were correlated with differentially expressed miRNAs in HD brains.
miRNAs with at least one nominal p-value < 0.05 are shown. Pearson correlation coefficients and features were independently hierarchically clustered.
Red boxes indicate positive correlations and blue boxes indicate negative correlations. Seven miRNAs in the left section are down-regulated in HD and
the ten miRNAs in the right section are up-regulated. Unsupervised clustering separated miRNA by their direction of fold change.
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cells expressing a mutant huntingtin fragment enhanced
cell survival [13], and miR-10b-5p has been observed to
facilitate neurodifferentiation [43]. Given its high levels of
differential expression, strong relationship to striatal in-
volvement and age at onset, more research into miR-10b-
5p is justified to understand its role in the pathogenesis of
HD, its potential as a biomarker of disease progression
and its potential as a therapeutic target.
The cell type most responsible for miRNA changes
cannot be determined from these data. Tissue homogen-
ate was used for sequencing, so the source of miRNA
signal is likely both neuronally and non-neuronally de-
rived. To determine the miRNA cellular specificity in
the brain, Jovicic et al. [16] measured miRNA expression
in cultured neurons, oligodendrocytes, microglia and as-
trocytes to find miRNAs enriched for each cell type.
Based upon this study, miRNAs found to be specifically
enriched in neuronal cultures (miR-129-3p, miR-129-5p,
miR-132, miR-135b, miR-431, miR-433) were all down-
regulated in our study whereas miRNAs enriched in
microglial cultures (miR-126-5p, miR-126-3p, miR-141,
miR-142-3p, miR-142-5p, miR-150, miR-200c and miR-
223) were all were up-regulated. According to these en-
richment categories, microglial activation miRNAs do
not relate to clinical features of the disease. Conversely,
three neuronal-related miRNAs, miR-129-3p/5p and
miR-132, were associated with pathological involvement
(see Figure 5). Therefore, we hypothesize that differential
expression of those miRNAs related to neuron function
may also relate to the HD pathology.
The relationship of the expression of miRNAs with
Vonsattel grade suggests expression changes may occur
early in the disease process (see Figure 2). Many of these
miRNA changes appear present ordinal trends with an
increase (miR-10b-5p, miR-10b-3p, miR-302a, miR-
196a-5p, miR-196b-5p) or decrease (miR-663b, miR-
4488, miR-4449) in their expression across grade. In
particular, miR-10b-5p was significantly different across
all groups, with the exception of the asymptomatic
grade 0 brains and we believe this is an issue of statis-
tical power. It is possible that the expression of these
miRNAs may relate to HTT aggregation or proteasomal
A B
C
Figure 5 Gene ontology terms are similar for mRNA targets of clinically relevant de-regulated miRNAs. (A) Illustrates the overlap in GO
Biological Processes between targets of increased miRNA (in orange) and decreased miRNA (in blue) in HD. The x-axis shows the number of gene
ontology terms that fall within a given semantic term set, and the y-axis lists the top twenty enriched terms for each set of miRNA targets. Darker
colored points represent terms with higher significance and the size of the points represents the union of all genes that fall within a given the
term. A number of terms, including “nervous system development” as well as terms relating to transcriptional regulation are shared across up- and
down-regulated miRNA target groups. The similarity targets of up-regulated miRNA (in orange) and down-regulated miRNA (in blue) for GO Molecular
Function are seen in (B) and for GO Cellular Component in (C).
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degradation, as intranuclear inclusions are observed in
pre-symptomatic HD [44] and the density of aggregate
formation continues over the course of the disease.
Three miRNAs (miR-10b-3p/5p, miR-302a) related to
H-V striatal score, independent of the CAG repeat expan-
sion size and for miR-10b-5p, independent of cortical in-
volvement. These results suggest the relationship of
miRNA expression to striatal involvement in the disease is
independent of cortical involvement, which is a critical
finding, because prefrontal cortex was the source of tissue
profiled in these studies.
Based on correlation (see Figure 4), up-regulated miR-
NAs clustered together based on their relationships to
clinical features. Generally, these miRNAs had strong,
positive associations to striatal and cortical H-V scores,
weak positive association with disease duration and
strong negative associations to onset and death age.
Down-regulated miRNAs clustered together as well but
were less defined in their relationships to clinical features.
Most down-regulated miRNAs were inversely associated
with H-V scores and duration, opposite to up-regulated
miRNAs. These patterns suggest that decreasing up-
regulated miRNAs and increasing down-regulated miRNA
may be beneficial. However, it remains to be determined
which altered miRNAs are compensatory and potentially
neuroprotective and which are pathological and neuro-
toxic. Furthermore, it is unknown whether these changes
are consequential, revealing important molecular aspects
of the disease process, or are simply innocent by-products.
However, using target analysis and GO term enrich-
ment, we observed predicted targets of both up- and
down-regulated miRNAs shared many of the same bio-
logical processes and overall systems relating to “nervous
system development.” Both sets contained several tran-
scriptional regulation related terms (transcriptional regula-
tion, DNA-dependent or RNA polymerase II, chromatin
remodeling, post-transcriptional gene regulation, chroma-
tin remodeling, etc.). Both sets of genes contained terms
on metabolism, apoptosis, metal-binding and ubiquitin.
Disruption to any of these systems may affect neuron
health. Overall, these finding imply both up- and down-
regulated miRNAs many be part of the same or similar
biological pathways.
Conclusions
Our findings identify many miRNA alterations in HD
brain and a large number of these are related to clinical
manifestations of the disease, where the signal is inde-
pendent of the size of the CAG repeat expansion. The
study of Grade 0 cases suggests that miR-10b-5p expres-
sion changes may occur pre-symptomatically. Up- and
down-regulated miRNAs may target genes in similar
biological systems, and these genes are involved in tran-
scriptional regulation, neuronal development and other
important aspects surrounding neuron function. These
miRNAs represent attractive candidates for predicting
onset age and overall health of the striatum in HD. Stud-
ies pursuing these miRNAs as potential biomarkers for
HD are in progress, as miRNAs may be detectable in
peripheral fluids [45] and thus have potential to function
as accessible biomarkers for disease stage, rate of pro-
gression, treatment efficacy and other important clinical
characteristics of HD.
Methods
Sample information
Frozen brain tissue from prefrontal cortex Brodmann
Area 9 (BA9) was obtained from the Harvard Brain and
Tissue Resource Center McLean Hospital, Belmont MA,
Banner Sun Health Research Institute, Sun City, Arizona
[46] and Human Brain and Spinal Fluid Resource Center
VA, West Los Angeles Healthcare Center, Los Angeles,
CA. 26 Huntington’s disease (HD) samples, 2 asymp-
tomatic HD gene carriers, and 36 neurologically and
neuropathologically normal control samples were se-
lected for the study (Additional file 1: Tables S1 and
Additional file 2: Table S2). HD subjects had no evidence
of other neurological disease based on neuropathological
examination. HD samples and controls were not differ-
ent in postmortem interval (PMI) (p-value = 0.69), RNA
integrity number (p-value = 0.08) or gender (p-value =
0.51) but differed in ages at death (HD mean age =59.5,
control mean age =68.6; p-value = 0.01) (see Table 1).
Asymptomatic HD samples did not differ in age at death
(mean age =67.5) in comparison to HD or control sam-
ples (control p-value = 0.92; HD p-value = 0.40). Infor-
mation on CAG genotype, onset age, death age, disease
duration, Vonsattel grade, Hadzi-Vonsattel striatal and
cortical scores for HD samples can be found in Additional
file 2: Table S2.
Total RNA was isolated using QIAzol Lysis Reagent
and purified using miRNeasy MinElute Cleanup col-
umns. RNA quality for sequencing was assessed using
either Agilent’s BioAnalyzer 2100 system and RNA 6000
Nano Kits to determine RNA Integrity Number or Agi-
lent 2200 TapeStation and Agilent DNA ScreenTape
assay RNA Quality Number. For each brain sample, 1 ug
of RNA was used to construct sequencing libraries using
Illumina’s TruSeq Small RNA Sample Prep Kit, accord-
ing to the manufacturer’s protocol, and sequenced using
1x51nt single-end reads on Illumina’s HiSeq 2000 system
at Tufts University (http://tucf-genomics.tufts.edu/) or
the Michigan State sequencing core facility (http://rtsf.
natsci.msu.edu/genomics/).
miRNA sequence analysis
Reads were quality filtered, removing reads below 80%
Q20, using FASTX-toolkit FASTQ quality filter (version
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0.0.13.2, http://hannonlab.cshl.edu/fastx_toolkit/). Adapter
sequence (5′-TGGAATTCTCGGGTGCCAAGG-3′) was
removed from the 3′ end of all reads using cutadapt 1.2.1
(http://code.google.com/p/cutadapt/) and reads less than
15 nucleotides in length were discarded [47]. Reads were
collapsed using FASTX-toolkit FASTA/Q collapser. Reads
were aligned to the UCSC human reference genome (build
hg19) using Bowtie version 1.0.0, using no mismatch
alignments and a limit of 200 multiple mapping instances
[48]. Aligned reads that overlapped with the human
miRNA annotation, miRBase version 20, (http://www.mir-
base.org/ftp.shtml) were identified using BEDTools Inter-
sectBed [49]. Reads longer than 27 bases were removed.
miRNA reads were counted if ±4 nucleotides from the
mature, annotated 5′ start coordinates. Reads that mapped
to multiple locations, represented by a single mature
miRNA, were recorded as a single miRNA count. Multi-
mapped reads represented by multiple mature miRNA an-
notations were discarded. Additional file 3: Table S3 for
read statistics. R version 3.1.0 and Bioconductor 2.1.4 ver-
sion were used for differential expression analysis. DESeq2
version 1.40.0 was used for estimation of library size and
correction, as well as variance-stabilizing transformation
(VST) [50,51]. miRNAs with a mean less than 2 raw read
counts across all samples were removed. Batch effect was
corrected using ComBat with default options through the
Bioconductor package sva 3.10 [52,53]. All samples were
included in VST and batch correction. Using 36 controls
and 26 HD grades 2–4, differential expression analysis was
performed with LIMMA version 3.20.8 [54,55], adjusting
for age at death in the model. Q-values were FDR-adjusted
for 938 comparisons. The unprocessed fastq files, normal-
ized miRNA counts and results from miRNA differential
expression analysis have been deposited in NCBI’s Gene
Expression Omnibus [56], and are accessible through
GEO Series accession number GSE64977 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64977).
Firefly miRNA assay
A panel of 16 differentially expressed miRNAs with moder-
ate to high expression (miR-10b-5p, miR-194-5p, miR-223-
3p, miR-132-3p, miR-144-5p, miR-148a-3p, miR-486-5p,
miR-363-3p, miR-199a-5p, miR-16-2-3p, miR-142-3p, miR-
34c-5p, miR-129-5p, miR-433-3p, miR-885-5p, miR-346)
and six stably expressed miRNAs in sequencing (miR-9-5p,
miR-92a-3p, miR-98-5p, miR-101-3p, miR-151a-3p, miR-
338-3p) was used for validation. In a 96-well filter plate,
Firefly Multimix (Firefly BioWorks, www.fireflybio.com)
was incubated with 25ul Hybridization Buffer and 25ul total
RNA at a concentration of 1 ng/ul at 37°C for 60 minutes.
After rinsing to removing unbound RNA, 75ul of Labeling
Buffer was added to each well, and the plate was incubated
for 60 minutes at room temperature. Adapted-modified
miRNAs were released from the particles using 90°C water,
and PCR amplified using a fluorescently-label primer set.
PCR product was hybridized to fresh Firefly Multimix for
30 minutes at 37°C and re-suspended in Run Buffer for
readout. Particles were scanned on an EMD Millipore
Guava 8HT flow cytometer. Raw output was background
subtracted, normalized using the geometric mean of the six
normalizer miRNAs and log-transformed. LIMMA version
3.20.8 [54] was used to calculate significance.
HD feature analysis
For analysis of miRNA expression to Vonsattel grade,
Tukey HSD statistics and compact letter display were
generated by the multcomp R package [57]. CAG-
adjusted age of onset was calculated using the logarith-
mic model from Djousse et al. 2003 [4]. Hadzi-Vonsattel
striatal and cortical scores were measured in 523 HD
brain samples as previously described [28]. Samples with
greater than 55 repeats or missing CAG information
were excluded from analysis, leaving 346 samples. To
provide robust residual estimates for the subset of sam-
ples included in the sequencing project, H-V striatal
score, H-V cortical score, death age and disease duration
features were corrected for CAG size by modeling each
feature to CAG size within the HD dataset (N = 346)
and the residuals from the model were extracted for
each sample (Additional file 7: Figure S1) [28]. VST-
batch corrected counts were used for all subsequent
analyses. CAG-adjusted residuals and miRNA expression
relationships were analyzed using linear regressions. Co-
variates (PMI, RIN, age at death) were not included in lin-
ear models, as neither PMI nor RIN were determined to
have an effect on the outcome of the results. Age at death
could not be included in the analysis due to the relation-
ship of age at death and HD clinical pathology. Q-values
were FDR-adjusted for 75 differentially expressed miRNA
contrasts for linear regressions were reported.
For the cluster analysis in Figure 4, Pearson correla-
tions for miRNA expression to clinical feature were per-
formed and those miRNAs with p-values < 0.05, without
adjustment for multiple comparisons, were reported.
Pearson correlation coefficients were hierarchically clus-
tered using Euclidean distance and unsupervised complete
clustering method through the R-package pheatmap ver-
sion 0.7.7.
Target prediction and gene ontology enrichment
Targetscan, release 6.2 [33] was used to select mRNA
targets of miRNAs with at least one relationship to clin-
ical feature. Fourteen miRNAs were available on Tar-
getscan and twelve miRNAs had unique seed sequences.
Targets were removed with total context scores ≥ −0.1.
miRNAs with positive fold change in HD (miR-106a/
302a-5p, miR-196a/miR-196b, miR-302a-3p, miR-363,
miR-10b, miR-615-3p), and negative fold change in HD
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(miR-129-3p, miR-129-5p, miR-132-3p, miR-4449, miR-
4488, miR-490-5p) were stratified for gene ontology
term (GO) enrichment analysis. GO term enrichment
for “biological processes,” “molecular function,” and “cel-
lular component,” was performed using topGO [58] with
the “weight01” algorithm and Fisher statistic within the
R statistical environment. A weighted Fisher p-value < 0.05
threshold was used to select significant GO enrichment.
Significant terms were collapsed by semantic similarity
using the program REVIGO [59], with p-value included
for each term and using the “Small (0.5)” similarity setting.
The union of genes from REVIGO “parent” terms was cal-
culated using topGO’s genes.in.term function.
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striatal score and H-V cortical score were computed from data derived from
346 HD brain samples with CAG repeat sizes <56 from Hadzi et al. [28]. Red
dots represent samples studied in these analyses.
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